SCHEMBL30989898

SCHEMBL30989898

CCN(C)C(=O)c1cc(Cl)cnc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 1/20 0.42
▸ PIK3C3 Q8NEB9 1/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.38
▸ TSHR P16473 2/20 0.38
▸ GAA P10253 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ LIPE Q05469 2/20 0.37
▸ F10 P00742 2/20 0.36
▸ BCHE P06276 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MCOLN3 Q8TDD5 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ F2 P00734 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25228040 0.82 GPBAR1 (0.43) GPBAR1PIK3C3FFAR4TSHRLIPE
SCHEMBL30989930 0.82 HSP90AA1 (0.52) GAAMEN1KMT2AALDH1A1HSP90AA1
SCHEMBL30989886 0.81 CLK1 (0.44) GPBAR1PIK3C3FFAR4GAAPOLB
SCHEMBL30989848 0.81 MAPT (0.43) GPBAR1LIPEMEN1KMT2AMAPK1
SCHEMBL30989813 0.79 CLK1 (0.43) GPBAR1PIK3C3FFAR4POLBHSP90AA1
SCHEMBL30989786 0.79 RXFP1 (0.45) GPBAR1PIK3C3MEN1KMT2AMCOLN3
SCHEMBL30989921 0.77 RIPK1 (0.45) GPBAR1PIK3C3GAAALDH1A1MAPT
SCHEMBL30989909 0.77 CLK1 (0.48) MEN1KMT2AMAPK1ALDH1A1POLB
SCHEMBL9653496 0.77 KDM4E (0.45) GPBAR1FFAR4TSHRLIPEMEN1
SCHEMBL9656790 0.77 FFAR4 (0.43) GPBAR1FFAR4TSHRLIPEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback